Preview

ПО МАТЕРИАЛАМ КОНСЕНСУСА ЕВРОПЕЙСКОЙ ГРУППЫ ПО ИЗУЧЕНИЮ ОФТАЛЬМОПАТИИ ГРЕЙВСА

https://doi.org/10.14341/ket20073413-26

Полный текст:

Аннотация

Материал подготовлен и адаптирован О.И. Виноградской и В.В. Фадеевым

Об авторе

- -



Список литературы

1. Wiersinga W.M., Perros P., Kahaly G.J. et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Garves' Orbitopathy recommendations to generalists, specialists and clinical researchers // Eur. J. of Endocrinol. 2006. V. 155. P. 387—389.

2. Perros P., Baldeschi L., Boboridis K. et al. A questionnaire survey on the management of Graves' orbitopathy in Europe // Eur. J. of Endocrinol. 2006. V. 155. P. 207—211.

3. Bartalena L., Pinchera A., Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives // Endocrine Reviews. 2000. V. 21. P. 168—199.

4. Perros P., Dickinson A.J. Ophthalmopathy. In Werner's & Ingbar's The Thyroid - A Fundamental and Clinical Text, edn 9, ch 23B pp 474-487: Eds. L.E. Braverman, R.D. Utiger. Philadelphia: Lippincott Williams & Wilkins, 2005.

5. Weetman A.P. Graves' disease // New England J. of Med. 2000. V. 343. P. 1237—1248.

6. Wiersinga W.M., Prummel M.F. Pathogenesis of Graves' ophthalmopathy - current understanding // J. of Clin. Endocrinol. Metab. 2001. V. 86. P. 501—503.

7. Ludgate M., Baker G. Inducing Graves' ophthalmopathy // J. of Endocrinol. Investigat. 2004. V. 27. P. 211—215.

8. Lazarus J.H., Marino M. Orbit-thyroid relationship. In Graves' orbitopathy: a multidisciplinary approach: Eds. W.M. Wiersinga, G. Kahaly. Basel: Karger, 2007.

9. Orgiazzi J. Pathogenesis. In Graves' orbitopathy: a multidisciplinary approach: Eds. W.M. Wiersinga, G. Kahaly. Basel: Karger, 2007.

10. Bartalena L., Tanda M.L., Piantanida E. Lai A., Pinchera A. Relationship between management of hyperthyroidism and course of the ophthalmopathy // J. of Endocrinol. Investigat. 2004. V. 27. P. 288—294.

11. Wiersinga W.M., Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy // Thyroid. 2002. V. 12. P. 855—860.

12. Bartalena L., Marcocci C., Pinchera A. Graves' ophthalmopathy: a preventable disease? // Eur. J. of Endocrinol. 2002. V. 146. P. 457—461.

13. Hagg E., Asplund K. Is endocrine ophthalmopathy related to smoking? // Brit. Med. J. 1987. V. 295. P. 634—635.

14. Bartalena L., Martino E., Marcocci C. et al. More on smoking habits and Graves' ophthalmopathy // J. of Endocrinol. Investigat. 1989. V. 12. P. 733—737.

15. Shine B., Fells P., Edwards O.M., Weetman A.P. Association between Graves' ophthalmopathy and smoking // Lancet. 1990. V. 335. P. 1261—1264.

16. Prummel M.F., Wiersinga W.M. Smoking and risk of Graves' disease // J. of Am. Med. Associat. 1993. V. 269. P. 479—482.

17. Winsa B., Mandahl A., Karlsson F.A. Graves' disease, endocrine ophthalmopathy and smoking // Acta Endocinol. (Copenhagen). 1993. V. 128. P. 156—160.

18. O'Hare J.A., Georghegan M. Cigarette smoking as a promoter of Graves' disease // Eur. J. of Intern. Med. 1993. V. 4. P. 289—292.

19. Nunery W.R., Martin R.T., Heinz G.W., Gavin T.J. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease // Ophthalm. Plast. Reconstruct. Surg. 1993. V.9. P. 77—82.

20. Pfeilschifter J., Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption // Clin. Endocrinol. (Oxford). 1996. V. 45. P. 477—481.

21. Vestergaard P. Smoking and thyroid disorders - a meta-analysis // Eur. J. of Endocrinol. 2002. V. 146. P. 153—161.

22. Hegedus L., Brix T.H., Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy // J. of Endocrinol. Investigat. 2004. V. 27. P. 265—271.

23. Thornton J., Kelly S.P., Harrison R.A., Edwards R. Cigarette smoking and thyroid eye disease: a systematic review // Eye. 2006. V. 20. P. 1—11.

24. Bartalena L., Marcocci C., Bogazzi F. et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism // New England J. of Med. 1989. V. 321. P. 1349—1352.

25. Tallstedt L., Lundell G., Terring O. et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group // New England J. of Med. 1992. V. 326. P. 1733—1738.

26. Bartalena L., Marcocci C., Bogazzi F. et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy // New England J. of Med. 1998. V. 338. P. 73—78.

27. Bartalena L., Marcocci C., Tanda M.L. et al. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy // Ann. of Intern. Med. 1998. V. 129. P. 632—635.

28. Eckstein A., Quadbeck B., Mueller G. et al. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy // Brit. J. of Ophthalmol. 2004. V. 87. P. 773—776.

29. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism // Acta Endocrinol. (Copenaghen). 1989. V. 121 (Suppl. 2). P. 185—189.

30. Prummel M.F., Wiersinga W.M., Mourits M.P. et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy // Archiv, of Intern. Med. 1990. V. 150. P. 1098—1101.

31. Tallstedt L., Lundell G., Blomgren H., Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine therapy? // Eur. J. of Endocrinol. 1994. V. 130. P. 494—497.

32. Marcocci C., Bartalena L., Bogazzi F. et al. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism // Thyroid. 1992. V. 2. P. 171—178.

33. Marcocci C., Bruno-Bossio G., Manetti L. et al. The course of Graves' ophthalmopathy is not influenced by near-total thyroidectomy: a case-control study // Clin. Endocrinol. 1999. V. 51. P. 503—506.

34. Menconi F., Marino M., Pinchera A. et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids // J. of Clin. Endocrinol. Metab. 2007. V. 92. P. 1653—1658.

35. Jarhult J., Rudberg C., Larsson E. et al. Graves' disease with moderate-severe endocrine ophthalmopathy — long term results of a prospective, randomized study of total or subtotal thyroid resection // Thyroid. 2005. V. 15. P. 1157—1164.

36. Perros P., Kendall-Taylor P., Neoh C. et al. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy // J. of Clin. Endocrinolog. Metab. 2005. V. 90. P. 5321—5323.

37. Dederichs B., Dietlein M., Jenniches-Kloth B. et al. Radioiodine therapy of Graves' hyperthyroidism in patients without preexisting ophthalmopathy: can glucocorticoids prevent the development of new ophthalmopathy? // Experiment. Clin. Endocrinol. Diabete. 2006. V. 114. P. 366—370.

38. Eckstein A.E., Plicht M., Lex H. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease // J. of Clin. Endocrinol. Metab. 2006. V. 91. P. 3464—3470.

39. Bartalena L. Glucocorticoids for Graves' ophthalmopathy: how and when // J. of Clin. l Endocrinol. Metab. 2005. V. 90. P. 5497—5499.

40. Uddin J.M., Davies P.D. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection // Ophthalmol. 2002. V. 109. P. 1183—1187.

41. Terwee C.B., Gerding M.N., Dekker F.W. et al. Development of a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy // Brit. J. of Ophthalmol. 1998. V. 82. P. 773—779.

42. Mourits M.P., Koornneef L., Wiersinga W.M. et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach // Brit. J. of Ophthalmol. 1989. V. 73. P. 639—644.

43. Mourits M.P., Prummel M.F., Wiersinga W.M., Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy // Clin. Endocrinol. (Oxford). 1997. V. 47. P. 9—14.

44. Dickinson A.J., Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of detailed protocol with comparative photographs for objective assessment // Clin. Endocrinol. (Oxford). 2001. V. 55. P. 283—303.

45. Rose G.E. Postural visual obscurations in patients with inactive thyroid eye disease; a variant of “hydraulic” disease // Eye. 2006. V. 20. P. 1178—1185.

46. Marcocci C., Bartalena L., Tanda M.L. et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, singleblind, randomized study // J. of Clin. Endocrinol. Metab. 2001. V. 86. P. 3562—3567.

47. Macchia P.E., Bagattini M., Lupoli G. et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy // J. of Endocrinol. Investigat. 2001. V. 24. P. 152—158.

48. Kauppinen-Makelin R., Karmi A., Leinonen E. et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy // Acta Ophthalmol. Scandin. 2002. V. 80. P. 316—321.

49. Kahaly G.J., Pitz S., Hommel G., Dittmar M. Randomized, single-blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy // J. of Clin. Endocrinol. Metab. 2005. V. 90. P. 5234—5240.

50. Ng C.M., Yuen H.K.L., Choi K.L. et al. Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study // Hong Kong Med. J. 2005. V.11. P. 322—330.

51. Hart Frantzco R.H., Kendall-Taylor P., Crombie A., Perros P. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome // J. of Ocular Pharmacol. and Therapeut. 2005. V. 21. P. 328—336.

52. Soares-Welch C.V., Fatourechi V., Bartley G.B. et al. Optic neuropathy of Graves disease: results of transantral orbital decompression and long-term follow-up in 215 patients // Am. J. of Ophthalmol. 2003. V. 136. P. 433—441.

53. Wakelkamp I.M., Baldeschi L., Saeed P. et al. Surgical or medical decompression as a first-line treatment in Graves' ophthalmopathy? A randomized controlled trial // Clin. Endocrinol. (Oxford). 2005. V. 63. P. 323—328.

54. Akamizu T., Kaneko H., Noguchi N. et al. Moisture chamber for management of corneal ulcer due to Graves' ophthalmopathy // Thyroid 2000. V. 10. P. 1123—1124.

55. Heinz C., Eckstein A., Steuhl H.P., Meller D. Amniotic membrane transplantation for reconstruction of corneal ulcer in Graves' ophthalmopathy // Cornea. 2004. V. 23. P. 524—526.

56. Bartalena L., Marcocci C., Chiovato L. et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone // J. of Clin. Endocrinol. Metab. 1983. V. 56. P. 1139—1144.

57. Kahaly G., Schrezenmeir J., Krause U. et al. Ciclosporin and prednisone vs. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study // Eur. J. of Clin. Investigat. 1986. V. 16. P. 415—422.

58. Prummel M.F., Mourits M.P., Berghout A. et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy // New England J. of Med. 1989. V. 321. P. 1353—1359.

59. Prummel M.F., Mourits M.P., Blank L. et al. Randomised double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy // Lancet. 1993. V. 342. P. 949—954.

60. Kung A.W., Michon J., Tai K.S., Chan F.L. The effect of somatostatin versus corticosteroids in the treatment of Graves' ophthalmopathy // Thyroid. 1996. V. 6. P. 381—384.

61. Kahaly G.J., Pitz S., Muller-Forell W., Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy // Clin. Experim. Immunol. 1996. V. 106. P. 197—202.

62. Marcocci C., Bartalena L., Panicucci M. et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study // Clin. Endocrinol. (Oxford). 1987. V. 27. P. 33—42.

63. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis // Arthrit. Rheumatol. 2001. V. 44. P. 1496—1503.

64. Compston J. on behalf of Guidelines Writing Group. Glucocorticoid-induced osteoporosis guidelines for prevention and treatment. Royal College of Physicians of London, UK 2002.

65. Wiersinga W.M., Prummel M.F. Graves' ophthalmopathy: a rational approach to treatment // Trends in Endocrinol. Metab. 2002. V. 13. P. 280—287.

66. Weissel M., Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe eye disease // Thyroid. 2000. V. 10. P. 521.

67. Marino M., Morabito E., Brunetto M.R. et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy // Thyroid 2004. V. 14. P. 403—406.

68. Le Moli R., Baldeschi L., Saeed P. et al. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy // Thyroid. 2007. V. 17. P. 357—362.

69. Bartalena L., Marcocci C., Tanda M.L. et al. Orbital radiotherapy for Graves' ophthalmopathy // Thyroid. 2002. V. 12. P. 245—250.

70. Kahaly G.J., Rosler H.P., Pitz S., Hommel G. Low-versus highdose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial // J. of Clin. Endocrinol. Metabol. 2000. V. 85. P. 102—108.

71. Nakahara H., Noguchi S., Murakami N. et al. Graves' ophthalmopathy: MR evaluation of 10 Gy vs. 24 Gy irradiation combined with systemic corticosteroids // Radiolog. 1995. V. 196. P. 857—862.

72. Mourits M.P., van Kempen-Harteveld M.L., Garcia M.B. et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled stuy // Lancet 2000. V. 355. P. 1505—1509.

73. Prummel M.F., Terwee C.B., Gerding M.N. et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy // J. of Clin. Endocrinol. Metab. 2004. V. 89. P. 15-20.

74. Gorman C.A., Garrity J.A., Fatourechi V. et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' orbitopathy // Ophthalmol. 2001. V.P. 1523-1534.

75. Marquez S.D., Lum B.L., McDougall I.R. et al. Long-term results of irradiation for patients with Graves' ophthalmopathy // Internat. J. of Radiat. Oncol. Biolog. and Phys. 2001. V. 51. P. 766-774.

76. Marcocci C., Bartalena L., Rocchi R. et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy // J. of Clin. Endocrinol. Metab. 2003. V. 88. P. 3561-3566.

77. Wakelkamp I.M., Tan H., Saeed P. et al. Orbital irradiation for Graves' ophthalmopathy : is it safe? A long-term follow-up study // Ophthalmol. 2004. V. 111. P. 1557-1562.

78. Robertson D.M., Buettner H., Gorman C.A. et al. Retinal microvascular abnormalities in patients treated with external radiation for Graves ophthalmopathy // Archiv. of Ophthalmol. 2003. V. 121. P. 652-657.

79. Wiersinga W.M. Management of Graves' ophthalmopathy // Natur. Clin. Pract. Endocrinol. Metab. 2007. V. 3. P. 396-404.

80. Viebahn M., Marricks M.E., Osterloh M.D. Synergism between diabetic and radiation retinopathy: case report and review // Brit. J. of Ophthalmol. 1991. V. 75. P. 29-32.

81. Marcocci C., Bartalena L., Bogazzi F. et al. Orbital radiotheraphy combined with high-dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study // J. of Endocrinol.l Investigat. 1991. V. 14. P. 853-860.

82. Dickinson A.J., Vaidya B., Miller M. et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy // J. of Clin. Endocrinol. Metab. 2004. V. 89. P. 5910-5915.

83. Wemeau J.L., Caron P., Beckers A. et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study // J. of Clin. Endocrinol. Metab. 2005. V. 90. P. 841-848.

84. Stan M.N., Garrity J.A., Bradley E.A. et al. Randomized, doubleblind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy // J. of Clin. Endocrinol. Metab. 2006. V. 91. P. 4817-4824.

85. Chang T.-C., Liao S.L. Slow-release lanreotide in Graves' ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial // J. of Endocrinolog. Investigat. 2006. V. 29. P. 413-422.

86. Perros P., Weightman D.R., Crombie A.L., Kendall-Taylor P. Azathioprine in the treatment of thyroid-associated ophthalmopathy // Acta Endocrinolog. (Copenhagen). 1990. V. 122. P. 8-12.

87. Kahaly G., Lieb W., Muller-Forell W. et al. Ciamexone in endocrine orbitopathy. A randomized, double-blind, placebocontrolled study // Acta Endocrinolog. (Copenhagen). 1990. V. 122. P. 13-21.

88. Kahaly G., Pitz S., Muller-Forell W., Hommel G. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy // Clin. Experim. Immunol. 1996. V. 106. P. 197-202.

89. Antonelli A., Saracino A., Alberti B. et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy // Acta Endocrinolog. (Copenhagen) 1992. V. 126. P. 13-23.

90. Salvi M., Vannucchi G., Campi I. et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study // Eur. J. of Endocrinol. 2007. V. 156. P. 33-40.

91. Paridaens D., van den Bosch W.A., van der Loos T.L. et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study // Eye. 2005. V. 19. P. 1286-1289.

92. Mourits P., Koornneef L., van Mourik-Noordenbos A.M. et al. Extraocular muscle surgery for Graves' ophthalmopathy: does prior treatment influence surgical outcome? // Brit. J. of Ophthalmol. 1990. V. 74. P. 481-483.

93. Baldeschi L., MacAndie K., Koetsier E. et al. The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in Graves' ophthalmopathy // Am. J. of Ophthalmol. 2007 (in press).

94. Baldeschi L. Decompression surgery for thyroid-related orbitopathy: state of the art and unresolved issues. In Essentials in ophthalmology: orbit and oculoplastic. Edn 9: Eds R. Guthoff // J. Katovitz. Berlin: Springer (in press).

95. Goldberg R.A., Christenbury J.D., Shorr N. Medial entropion following orbital decompression for dysthyroid ophthalmopathy // Ophthalm. Plast. Reconstruct. Surg. 1988. V. 4. P. 81-85.

96. Rose G.E., Lund V.J. Clinical features and treatment of late enophthalmos after orbital decompression: a condition suggesting cause for idiopathic "imploding antrum” (silent sinus syndrome) // Ophthalmol. 2003. V. 110. P. 819-826.

97. McCormick C.D., Bearden W.H., Hunts J.H., Anderson R.L. Cerebral vasospasm and ischemia after orbital decompression for Graves ophthalmopathy // Ophthalm. Plast. Reconstruct. Surg. 2004. V. 20. P. 347-351.

98. Carrasco J.R., Castillo I., Bolyk R. et al. Incidence of infraorbital hypesthesia and sinusitis after orbital decompression for thyroid-related orbitopathy: a comparison of surgical techniques // Ophthalm. Plast. Reconstruct. Surg. 2005. V. 21. P. 188-191.

99. Baldeschi L., Lupetti A., Vu P. et al. Reactivation of Graves' orbitopathy after rehabilitative orbital decompression // Ophthalmol. 2007. (Epub ahead of print.)

100. Baldeschi L., Wakelkamp I.M., Lindeboom R. et al. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients // Ophthalmol. 2006. V. 113. P. 874-878.

101. Baldeschi L., MacAndie K., Hintschich C. et al. The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia // Am. J. of Ophthalmol. 2005. V. 140. P. 642-647.

102. Wiersinga W.M., Prummel M.F., Terwee C.B. Effects of Graves' ophthalmopathy on quality of life // J. of Endocrinolog. Investigat. 2004. V. 27. P. 259-264.

103. Kahaly G.J., Petrak F., Hardt J., Pitz S., Egle U.T. Psychosocial morbidity of Graves' orbitopathy // Clin. Endocrinol. (Oxford). 2005. V. 63. P. 395-402.

104. Wiersinga W.M. Thyroid associated ophthalmopathy: pediatric and endocrine aspects // Pediatr. Endocr. Rev. 2004. V. 1 (Suppl 3). P. 513—517.

105. Krassas G.E., Gogakos A. Thyroid-associated ophthalmopathy in juvenile Graves' disease — clinical, endocrine and therapeutic aspects // J. of Pediatr. Endocrinol. Metab. 2006. V. 19. P. 1193—1206.

106. Krassas G.E., Segni M., Wiersinga W.M. Childhood Graves' ophthalmopathy: results of a European questionnaire study // Eur. J. of Endocrinol. 2005. V. 153. P. 515—520.

107. Krassas G.E., Wiersinga W.M. Smoking and autoimmune thyroid disease: the plot thickens // Eur. J. of Endocrinol. 2006. V. 154. P. 777—780.

108. Krassas G.E., Perros P. Prevention of thyroid-associated ophthalmopathy in children and adults: current views and management of preventable risk factors // Pediatr. Endocrinol. Rev. 2007. V. 4. P. 218—224.

109. Krassas G.E. Thyroid eye disease in children and adolescents: new therapeutic approaches // J. of Pediatr. Endocrinol. Metabol. 2001. V. 14. P. 97—100.


Для цитирования:


- -. ПО МАТЕРИАЛАМ КОНСЕНСУСА ЕВРОПЕЙСКОЙ ГРУППЫ ПО ИЗУЧЕНИЮ ОФТАЛЬМОПАТИИ ГРЕЙВСА. Клиническая и экспериментальная тиреоидология. 2007;3(4):13-26. https://doi.org/10.14341/ket20073413-26

For citation:


. PO MATERIALAM KONSENSUSA EVROPEYSKOY GRUPPY PO IZUChENIYu OFTAL'MOPATII GREYVSA. Clinical and experimental thyroidology. 2007;3(4):13-26. (In Russ.) https://doi.org/10.14341/ket20073413-26

Просмотров: 50


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-5472 (Print)
ISSN 2310-3787 (Online)